SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
==== Spinal cord ==== In spinal cord, KOR is expressed in the substantia gelatinosa and superficial laminae of the dorsal horn, where they modulate thermal nociception and chemical viscelar pain. They are concentrated in the upper laminae of the dorsal horn (laminae I–III) and within the posterolateral tract. The highest density was localized within the inner segment of lamina II, forming a dense band immediately dorsal to lamina III. 53% of KOR binding sites in the superficial dorsal horn (laminae I–II) are localized presynaptically on primary afferent terminals, with the remainder distributed postsynaptically.
== Possible implications for treatment == Several double blind studies experimented with low dose opioid antagonists, such as naltrexone, for treatment of autism. A 2014 systematic review showed statistically significant improvement in symptoms of irritability and hyperactivity in 77% of children treated with naltrexone. Core autism symptoms were unaffected. Side effects were mild and the drug was generally well tolerated. The number of children undergoing such therapy in the 10 analysed studies was 128.
Substance use disorders are among the more heavily stigmatized health conditions, and negative attitudes are documented among clinicians as well as among the general public. A systematic review of studies of health professionals in Western countries found that negative attitudes towards patients with substance use disorders were common, and that they were associated with poorer communication, less involvement of patients in decisions about their own care, and reduced engagement with treatment. A later systematic review of studies conducted in the United States reported similar findings among practising clinicians and trainees, and found that some educational and contact-based interventions reduced measured stigma; the authors cautioned that the studies were few, varied widely in method, and that none linked measured stigma to patient health outcomes. The arts are used in advocacy and public education about addiction. Artists (particularly those with lived experience of addiction and recovery) use their work to reduce stigma and to reframe addiction as a treatable health condition rather than a moral failing, an approach intended to promote public compassion and shift responses from the criminal-justice system toward the public-health system.
== History and etymology == Alanine was first synthesized in 1850 when Adolph Strecker combined acetaldehyde and ammonia with hydrogen cyanide. The amino acid was named Alanin in German, in reference to aldehyde, with the interfix -an- for ease of pronunciation, the German ending -in used in chemical compounds being analogous to English -ine.
native state, intermediate states, unfolded state, depends on the denaturant value; therefore, the global fluorescence signal of their equilibrium mixture also depends on this value. One thus obtains a profile relating the global protein signal to the denaturant value. The profile of equilibrium unfolding may enable one to detect and identify intermediates of unfolding. General equations have been developed by Hugues Bedouelle to obtain the thermodynamic parameters that characterize the unfolding equilibria for homomeric or heteromeric proteins, up to trimers and potentially tetramers, from such profiles. Fluorescence spectroscopy can be combined with fast-mixing devices such as stopped flow, to measure protein folding kinetics, generate a chevron plot and derive a Phi value analysis.
Sources: en.wikipedia.org
== Products and services == 7-Eleven in the United States sells Slurpee drinks, a partially frozen soft drink introduced in 1965 (Oklahoma's stores sold these as Icy Drink until 2020), and Big Gulp beverages, introduced in 1976. Other products include: 7-Select private-brand products, coffee, fresh-made daily sandwiches, fresh fruit, salads, bakery items, hot and prepared foods, gasoline, dairy products, carbonated beverages and energy drinks, juices, donuts, financial services, and product delivery services. 7-Eleven is known for its relatively large drink sizes and 24-hour accessibility. 7-Eleven offers beverages in sizes as large as 128 U.S. fluid ounces (3,800 mL) (Team Gulp). These beverage sizes were all among the largest sold soft drinks when they were introduced. 7-Eleven has often been associated with these large sodas in popular culture. For example, Mayor Michael Bloomberg's proposed ban on large sodas in New York City was frequently referred to as the 'Big Gulp ban'. However, the ban would not apply to 7-Eleven, as convenience and grocery stores in New York are regulated by the state rather than the city. In 2012, 7-Eleven changed the size of the Double Gulp from 64 ounces to 50 ounces (1478 mL). The older style cups were too wide at the base to fit into vehicle beverage holders. This size change was not a reaction to the aforementioned large soda ban proposal, according to a spokesperson. In February 2020, they opened a cashier-less location at the 7-Eleven headquarters in Irving, Texas.
At the end of the 1950s, the USSR constructed the first satellite—Sputnik 1, which marked the beginning of the Space Race—a competition to achieve superior spaceflight capability with the United States. This was followed by other successful satellites, most notably Sputnik 5, where test dogs were sent to space. On 12 April 1961, the USSR launched Vostok 1, which carried Yuri Gagarin, making him the first human to ever be launched into space and complete a space journey. The first plans for space shuttles and orbital stations were drawn up in Soviet design offices, but personal disputes between designers and management prevented their development. In terms of the Luna program, the USSR only had automated spacecraft launches with no crewed spacecraft. The N1—a Super heavy-lift launch vehicle intended to match the American Saturn V for a Soviet crewed moon landing—failed all four of its test launches, and the 'Moon' part of Space Race was won by the Americans. The Soviet public's reaction to the American moon-landing was mixed. The Soviet government limited the release of information about it, which affected the reaction. A portion of the populace did not give it attention, and another portion was angered. In the 1970s, specific proposals for the design of a space shuttle emerged, but shortcomings, especially in the electronics industry (rapid overheating of electronics), postponed it till the end of the 1980s. The first shuttle, the Buran, flew in 1988, but without a human crew. Another, Ptichka, endured prolonged construction and was canceled in 1991.
=== History === Emus were first reported as having been seen by Europeans when explorers visited the western coast of Australia in 1696. This was during an expedition led by Dutch captain Willem de Vlamingh who was searching for survivors of a ship that had gone missing two years earlier. The birds were known on the eastern coast before 1788, when the first Europeans settled there. The birds were first mentioned under the name of the "New Holland cassowary" in Arthur Phillip's Voyage to Botany Bay, published in 1789 with the following description:
The four substrates of this enzyme are 3-hydroxyphenylacetic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are homogentisic acid, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 3-hydroxyphenylacetate,NAD(P)H:oxygen oxidoreductase (6-hydroxylating). This enzyme is also called 3-hydroxyphenylacetate 6-monooxygenase. It participates in styrene degradation.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.